Versican is a potential therapeutic target in docetaxel-resistant prostate cancer

In the current study, we investigated a combination of docetaxel and thalidomide (DT therapy) in castration-resistant prostate cancer (CRPC) patients. We identified marker genes that predict the effect of DT therapy. Using an androgen-insensitive PC3 cell line, we established a docetaxel-resistant P...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncoscience
Main Authors: Arichi, Naoko, Mitsui, Yozo, Hiraki, Miho, Nakamura, Sigenobu, Hiraoka, Takeo, Sumura, Masahiro, Hirata, Hiroshi, Tanaka, Yuichiro, Dahiya, Rajvir, Yasumoto, Hiroaki, Shiina, Hiroaki
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2015
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4381710/
https://ncbi.nlm.nih.gov/pubmed/25859560
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares